

JOURNAL OF BIOMEDICINE AND TRANSLATIONAL RESEARCH

Copyright ©2021 by Faculty of Medicine Universitas Diponegoro and Indonesian Society of Human Genetics

Original Research Articles

Effect of Probiotic Supplementation on Sprague Dawley Rat Liver Histopathology Fed by High Fat High Fructose Diet

Ninung RD Kusumawati^{1*}, Damianus Galih Panunggal², Maria Mexitalia¹, Magdalena Sidhartani¹, Juwita Pratiwi¹, Agustini Utari¹

¹Departement of Pediatrics, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

²Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

Article Info

History

Received: 31 July 2021

Accepted: 27 Aug 2021

Available: 31 Aug 2021

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is an important cause of liver diseases. Gastrointestinal microbiota dysbiosis elicits and aggravates NAFLD into Non-Alcoholic Steatohepatitis (NASH) and cirrhosis, increasing morbidity and mortality. Microbial manipulation such as probiotic supplementation has been found to treat NAFLD and prevent reverse its progression. However, the study about the protective effect of probiotics on NAFLD is still limited.

Objective: This study aimed to evaluate the effect of probiotics on liver histopathology *Sprague-Dawley* rats which given a High-Fat-High-Fructose (HFHFr) diet

Methods: This study was a post-test-only control study group design. The samples were 21 *Sprague-Dawley* male rats in 7 – 8 weeks of age and were divided into three groups. The Control Group (C) was provided with a standard chow diet. The Non-Probiotic (NP) group was given a HFHFr diet for eight weeks. The Probiotic group (P) was given a HFHFr diet for eight weeks, and a combination of HFHFr and probiotic consisted of *Lactobacillus acidophilus*, *Bifidobacterium longum*, and *Streptococcus thermophilus* for the next eight weeks. Histopathological samples were obtained from liver biopsy to assess NAFLD activity score (NAS), and fibrosis stages. We analyzed the difference in histopathological results using the Fisher's Exact Test.

Results: We found a significant difference in NAFL and NAS Score between NP and P group. The P group was shown to have lower trends for NAFLD and NASH than the NP group, but not for fibrosis.

Conclusion: Probiotics supplementation reduced steatosis and inflammation of the liver

Keywords: Probiotic; NAFLD; Fibrosis; Histopathology

Permalink/ DOI: <https://doi.org/10.14710/jbtr.v7i2.11686>

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the most common chronic liver diseases in the paediatric population.¹ In patients with NAFLD, 16 % will develop advanced fibrosis, and 9.3% developing end-stage liver disease². Non-Alcoholic Fatty Liver Disease (NAFLD) is a group of disorders characterized by macrovesicular hepatic steatosis, fibrosis, and end-stage liver disease and occurs in individuals without association with alcohol consumption.³

Several risk factors are associated with induction and development of NAFLD and Nonalcoholic Steatohepatitis (NASH), such as type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome. Diets associated with those conditions including High-Fat-High-Fructose diet, will also affect liver function and development into NAFLD or NASH. High concentration of sugar and fat induces hepatic de novo lipogenesis. This type of diet also gives rise for endoplasmic reticulum stress, promoting mitochondrial dysfunction and elevating hepatocytes apoptosis.^{4,5}

Alterations in gut microbiota composition and function negatively impacts the host (dysbiosis) and play causal roles in developing NAFLD.⁶ As the liver receives major blood supply from the intestine, it has a particular susceptibility of intestinal microbiota metabolite.

* Corresponding author:

E-mail: roseadhiani@yahoo.co.id
(Ninung RD Kusumawati)

Dysbiosis caused endotoxins and toxic metabolite production that compromised intestinal permeability, increasing the entry of bacterial metabolites and components into the liver through the portal vein.⁷ The microbiota can aggravate NAFLD through various mechanisms, one of them is by influencing short-chain FAs (SCFAs) synthesis and lipogenesis, increasing liver fat deposition and resulting in steatosis.⁸ In a study in which gut microbiota collected from obese donors were transplanted into germ-free mice, the mice that received gut microbiota before donor's weight loss had higher levels of hepatic triglyceride and cholesterol than mice that received post-weight loss gut microbiota.⁶ This mechanism, combined with inflammation caused by toxic microbiota product (especially lipopolysaccharide), will damage the liver, progressing into NASH, cirrhosis, or even hepatocellular carcinoma.⁹

Specific measures to "balance" the intestinal microbiota to its normal state are widely studied.¹⁰ Studies showed the gut microbiota has a crucial role in the pathogenesis of NASH/NAFLD, support the hypothesis that microbiota manipulation is a potential and effective therapy as an alternative in the management of NAFLD/NASH.¹⁰ Probiotics, by WHO, are defined as live microorganisms which when administered in adequate amounts.¹¹ In several experiments with murine models, probiotic supplementation improved liver histology, reduced liver fat, decreased serum ALT, and reduced liver fibrosis.⁹ However, there was still limited data regarding the hepatoprotective effect of probiotic supplementation.

This study aims to determine the probiotic's role as protective agents against NAFLD and NASH in murine-models.

MATERIALS AND METHODS

We performed a murine-model post-test only control study group design conducted in Animal Experimental Laboratory in Faculty of Medicine Airlangga University, Surabaya, Indonesia. Bodyweight and the length of all rats were measured before the experiment. The samples were 21 *Sprague-Dawley* male rats at 7–8 weeks of age. After one week of acclimatization, we divided those samples into three groups. The Control Group (C) was provided with a standard chow diet for eight weeks. The Non-Probiotic (NP) group was given High-Fat-High-Fructose (HFHFr) diet for eight weeks. The Probiotic group (P) was given HFHFr diet for eight weeks, and a combination of HFHFr and probiotic supplementation consisted of *Lactobacillus acidophilus*, *Bifidobacterium longum*, and *Streptococcus thermophilus* for the next eight weeks. HFHFr diet consists of 59% of energy derived from fat, 30% from carbohydrates, and 11% from protein, and standard chow diet with 10% of energy derived from fat, 30% from protein, and 60% from carbohydrates.¹²

After treatment, all the rats were measured for post-test body weight and sacrificed. Histopathological samples were obtained from liver biopsy. We made 4µm slides of liver tissue and then stained them with routine hematoxylin-eosin and Masson stain to see the fibrosis. According to Kleiner et al., histopathological examination for assessing NAFLD Activity Score

(NAS) is comprised of steatosis, lobular inflammation, cellular ballooning, and fibrosis. (see table 1) We further evaluate the non-alcoholic fatty liver status by using the 5% steatosis as a cut-off point. NAFLD is defined by the presence of steatosis in >5% of hepatocytes, using only the 'steatosis grade' component of NAS. We also evaluate the NAS Score into three categories: Not NASH (Score 1–2), Borderline (Score 3–4), and NASH (Score 5–8). We also categorized the fibrosis stage using Kleiner score criteria.¹³

We presented the data in mean and standard deviation. Histopathological data is shown in cross-tabulation. Statistical analysis was carried out using the IBM SPSS Statistics 25.0 statistical program. We measured the difference in histopathological results using the Mann-Whitney test. Significant difference marked with p-value less than 0.05

This study protocol was approved by Ethical Committee of Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia No.82/EC/H/KEPK/FK-UNDIP/V/2019.

RESULTS

In this study, 21 rats were intervened and analyzed for histopathological analysis. Anthropometric measurements were shown in table 1. We found no significant difference between pre-test and post-test body weight. ($p > 0.05$) (see table 2)

Our histopathology results (see figure 1) were presented in cross-tabulation. Our control group did not develop NAFLD and NASH, although rats in those groups developed stage I fibrosis. We also found that in the probiotic group, there were fewer subjects developing NAFLD (see table 3), NASH (see table 4), and stage II fibrosis (see table 5)

Fisher's Exact analysis showed that compared to the NP group, the P group was shown to have lower trends for NAFLD ($p = 0.001$) and NASH ($p = 0.001$). It is shown that the P group had a lower trend for the fibrosis stage, although not statistically significant. ($p = 0.500$)

DISCUSSION

In present study we found that 8 weeks of HFHFr diet was already able to induce NAFL in our NP group. This finding was in parallel with a German murine-model study that found 8 weeks of HFHFr diet increased hepatic fat deposition. The same study also discovered altered intestinal barrier function in mice given the diet.¹⁴ A study in China found that high-fat diet induced dysbiosis in gastrointestinal microbiota and significantly increased the risk of metabolic syndrome, as shown by increased body weight, decreased insulin sensitivity, and marked dyslipidemia.¹⁵ It was supported by the fact that in dysbiosis, the altered gut microbiota used choline for metabolism, reducing free choline and inhibiting very-low-density lipoprotein (VLDL) excretion from the liver. Combined with increased intake of fat, especially short-chained fatty acid, excessive fat deposition was inevitable.¹⁶ We hypothesized that the HFHFr diet in our study was able to induce dysbiosis. We found no rats in P group had steatosis at the end of our treatment. This finding supported the fact that in this study, probiotic supplementation was able to reverse NAFL process. Our

Table 1. NAFLD Activity Score (NAS) Scoring System

Item	Score	Extent
NAS Components		
Steatosis Grade	0	< 5%
	1	5 – 33%
	2	>33 – 66%
	3	> 66%
Lobular Inflammation	0	No Foci
	1	<2 foci / 200x
	2	2 – 4 foci / 200x
Hepatocyte Ballooning	3	>4 foci / 200x
	0	None
	1	Few balloon cells
	2	Prominent ballooning
Fibrosis Stage (Evaluated separately from NAS)		
Fibrosis Stage	0	None
	1	Perisinusoidal or Periportal
	2	Perisinusoidal and portal/periportal
	3	Bridging fibrosis
	4	Cirrhosis

Table 2. Anthropometrics Characteristic of subjects

Group	Baseline Length	Pre-Test Weight	Post-Test Weight	p
		Mean ± SD		
C (n = 7)	15.65 ± 0.18	146.00 ± 37.60	169.29 ± 37.46	0.128*
NP (n = 7)	15.20 ± 0.22	134.29 ± 18.62	141.00 ± 14.92	0.203*
P(n = 7)	16.00 ± 1.00	118.43 ± 2.23	123.29 ± 11.57	0.203*

*Wilcoxon Test between Pre-Test and Post Test Weight

result was in line with several studies, as probiotic supplementation showed a significant decrease in NAFLD scores, steatosis, and improvement in the liver enzyme.^{17, 18}

We found that eight weeks of probiotics supplementation significantly reduce the NAS Score criteria (from NASH to Borderline) on all rats in the P group. This finding was in line with a previous study that significantly reduced inflammatory markers and steatosis following probiotic supplementation.¹⁹ Interestingly, despite the non-NAFLD status of all the P group rats, the liver histology is still classified with borderline, signifying some degree of inflammation. The key factors that play a role in converting mild fatty liver to NASH have not yet been determined. Some key factors include oxidative stress, lipid peroxidase, reactive metabolites, adipose tissue products, and gut microbiota dysbiosis.²⁰ These evidence were supported by a clinical trial in NASH patients treated with antibiotics. The patients' NASH degree were significantly lowered followed by microbiota change detected in stools.²¹ We hypothesized that dysbiosis induced by HFHFr diet might develop NASH, and eight weeks of probiotic supplementation only managed to reduce the steatosis, resulting in the 'Borderline' result in our probiotic group's NAS Score. We thought that our probiotic supplementation duration was not long enough to decrease the inflammatory process, as shown in other studies that supplied probiotics for a longer period.¹⁹

In addition, our study discovered that although insignificant, probiotic supplementation can decrease liver fibrosis. Another study also found that probiotic improved liver histology, reduced liver fat, decreased

serum ALT, and reduced liver fibrosis.⁹ Furthermore, another research found that probiotics supplementation also decreased the number of proinflammatory cytokines that also had a role in fibrosis.⁽²²⁾ We suggested that in this study, a significant decrease of NASH and fibrosis were mediated by this mechanism.

Interestingly, our study did not find any significant weight increase after the HFHFr diet. This finding was different from another study, as the samples were able to have a significant weight gain in the same amount of time.¹⁴ We thought that the main trigger for liver damage (and resolution) in our samples was mainly caused by dysbiosis. Bacterial overgrowth and increased translocation of bacteria to the portal and systemic circulation, increased lipopolysaccharide (LPS) levels, increased endotoxin, and activation of proinflammatory signals (TNF- α and IL-6) are seen in various chronic liver diseases, including NAFLD.²³ Probiotics supplementation improved gut mucosa permeability, as showed by increased expression of occluding and claudin-1 expression as vital markers of tight-junction integrity.²⁴

There were limitations of this study. The rats were fed *ad libitum*, so there were no data regarding daily/mean calorie intake for each group. Measurement of metabolic and inflammatory markers, as well as gut microbiota on each rat was not done in this study. We suggested a standardized calculation of dietary intake in each rat for better understanding the food dose in each group. For better understanding of the pathophysiological process, we advised in future studies to include the measurement of gut microbiota and other related biomarkers.




Figure 1. Liver histopathological slides from each group (H.E. stained, 200x
C = Control, NP = Non-Probiotic, P = Probiotic, Red Arrow = Inflammatory cell infiltration, Blue Arrow = Steatosis, Yellow Arrow = Ballooning)

CONCLUSION

In conclusion, eight weeks of probiotic supplementation reduced NAFLD incidence and decreased NAS score in *Sprague-Dawley* rats induced by the HFHF diet. The results of this study are expected to provide new insights for alternative medical treatment for patients with NAFLD. However, it is necessary to do further research on humans as subjects, with a longer probiotics supplementation time for more significant results, and consider the probiotics choice.

ACKNOWLEDGMENT

This paper is dedicated to Prof. Agus Firmansyah, MD, PhD, Pediatrician and I. Hartantyo, MD, Pediatrician. The authors thank the staff of Animal Experimental Laboratory in the Faculty of Medicine Airlangga University for their support in this study.

REFERENCES

1. Bush H, Golabi P, Younossi ZM. Pediatric Non-Alcoholic Fatty Liver Disease. *Children (Basel)*. 2017;4(6). doi: 10.3390/children4060048
2. Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. *Hepatol Commun*. 2018;2(2):199-210. doi: 10.1002/hep4.1134

Table 3. Steatosis Grade Interpretation According to Group

	Group	Steatosis Grade Interpretation		P
		Not NAFL	NAFL	
	C	7	0	0.001*
	NP	0	7	
	P	7	0	

*Fisher's Exact Test

Table 4. NAS Score Interpretation According to Group

	Group	NAS Score Interpretation			P
		Not NASH	Borderline	NASH	
	C	7	0	0	0.001*
	NP	0	0	7	
	P	0	7	0	

*Fisher's Exact Test

Table 5. Fibrosis Stage According to Group

	Group	Fibrosis Stage		P
		Stage 1	Stage 2	
	C	7	0	0.500*
	NP	6	1	
	P	7	0	

*Fisher's Exact Test

3. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. *World J Gastroenterol*. 2018;24(30):3361-73. doi: 10.3748/wjg.v24.i30.3361
4. The Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. *Clin Mol Hepatol*. 2013;19(4):325-48. doi: 10.3350/cmh.2013.19.4.325
5. Ekta, Gupta M, Kaur A, Singh TG, Bedi O. Pathobiological and molecular connections involved in the high fructose and high fat diet induced diabetes associated nonalcoholic fatty liver disease. *Inflamm Res*. 2020;69(9):851-67. doi: 10.1007/s00011-020-01373-7
6. Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. *Hepatology Res*. 2021;7:11. doi: 10.20517/2394-5079.2020.134
7. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut-liver axis and the intersection with the microbiome. *Nat Rev Gastroenterol Hepatol*. 2018;15(7):397-411. doi: 10.1038/s41575-018-0011-z
8. Yao M, Qv L, Lu Y, Wang B, Berglund B, Li L. An update on the efficacy and functionality of probiotics for the treatment of non-alcoholic fatty liver disease. *Engineering*. 2021;7(5):679-86. doi: 10.1016/j.eng.2020.01.017
9. Aron-Wisniewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. *Clin Microbiol Infect*. 2013;19(4):338-48. doi: 10.1111/1469-0691.12140
10. Matamoros S, Gras-Leguen C, Le Vacon F, Potel G, de La Cochetiere MF. Development of intestinal microbiota in infants and its impact on health. *Trends Microbiol*. 2013;21(4):167-73. doi: 10.1016/j.tim.2012.12.001
11. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. *J Clin Gastroenterol*. 2012;46(6):468-81. doi: 10.1097/MCG.0b013e3182549092

12. Emamat H, Noori M, Foroughi F, Rismanchi M, Eini-Zinab H, Hekmatdoost A. An Accessible and Pragmatic Experimental Model of Nonalcoholic Fatty Liver Disease. *Middle East J Dig Dis.* 2016;8(2):109-15. doi: 10.15171/mejdd.2016.15
13. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology.* 2005;41(6):1313-21. doi: 10.1002/hep.20701
14. Sellmann C, Priebes J, Landmann M, Degen C, Engstler AJ, Jin CJ, et al. Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. *J Nutr Biochem.* 2015;26(11):1183-92. doi: 10.1016/j.jnutbio.2015.05.011
15. He C, Cheng D, Peng C, Li Y, Zhu Y, Lu N. High-fat diet induces dysbiosis of gastric microbiota prior to gut microbiota in association with metabolic disorders in mice. *Front Microbiol.* 2018;9:639. doi: 10.3389/fmicb.2018.00639
16. Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, et al. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. *J Gastroenterol.* 2020;55(2):142-58. doi: 10.1007/s00535-019-01649-8
17. Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M. Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. *J Nutr.* 2018;148(8):1276-84. doi: 10.1093/jn/nxy088
18. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther.* 2014;39(11):1276-85. doi: 10.1111/apt.12758
19. Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. *Br J Nutr.* 2017;117(5):662-8. doi: 10.1017/S007114517000204
20. Başaranoğlu M, Örmeci N. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. *Turk J Gastroenterol.* 2014;25(2):127-32. doi: 10.5152/tjg.2014.7675
21. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. *Hepatology.* 2016;63(3):764-75. doi: 10.1002/hep.28356
22. Duseja A, Acharya SK, Mehta M, Chhabra S, Rana S, Das A, et al. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. *BMJ Open Gastroenterol.* 2019;6(1):e000315. doi: 10.1136/bmjgast-2019-000315
23. Martín-Domínguez V, González-Casas R, Mendoza-Jiménez-Ridruejo J, García-Buey L, Moreno-Otero R. Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. *Rev Esp Enferm Dig.* 2013;105(7):409-20. doi: 10.4321/s1130-01082013000700006
24. Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. *PLoS One.* 2012;7(10):e47713. doi: 10.1371/journal.pone.0047713